MarketExclusive.com reports today thatNeuralstem, Inc. (NYSE MKT: CUR)(CUR), an adult stem cell developer,published a blog post entitled “The accident was a horrible thing -but that horrible thing made Chris, at the end of his life, Superman.It's a happy irony if there is such a thing. I'm proud to have knownhim,” on the Company’s website(http://www.neuralstem.com/neuralstem-ceo-blog/147-spinal-cord-injury-trial),which was republished on TheChairmansBlog.com.
Neuralstem’sPresident and CEO, Richard Garr, reflected on the Company’srecently FDA approved Spinal Cord Injury Trial. He believes the FDAapproval “shows a growing comfort level with [Neuralstem’s]spinal cord cells, and [the Company’s] route of administration.”
Neuralstem'spatented technology enables the ability to produce neural stem cellsof the human brain and spinal cord in commercial quantities, and theability to control the differentiation of these cells constitutivelyinto mature, physiologically relevant human neurons and glia.Neuralstem completed dosing of the last patient in an FDA-approvedPhase I safety clinical trial for amyotrophic lateral sclerosis(ALS), often referred to as Lou Gehrig's disease, in August 2012; thetrial ends six months after that last surgery. Neuralstem has beenawarded orphan status designation by the FDA for its ALS celltherapy.
MarketExclusive.comprovides insights specifically for investors, business professionals,and entrepreneurs. It also aims to provide premium investmentnewsletters for serious investors in stocks, commodities, and otherpublicly traded vehicles.
- Pharmaceuticals & Drug Trials